Previous studies found that intravenous medications need to be administered to stroke victims within the so-called ‘golden hour’, that is, within 3 h (up to 4.5 h in certain patients), during which the patients have the best chance to survive and avoid debilitating, long-term neurological damage.59, 60 Compared to EPO, MK-X could have a higher chance of providing protection in damaged brain in stroke patients. This evidence concerns the gene EPO and Stroke.